ME02508B - Deuterisani derivati kateholamina i medikamenti koji obuhvataju pomenuta jedinjenja - Google Patents
Deuterisani derivati kateholamina i medikamenti koji obuhvataju pomenuta jedinjenjaInfo
- Publication number
- ME02508B ME02508B MEP-2016-167A MEP16716A ME02508B ME 02508 B ME02508 B ME 02508B ME P16716 A MEP16716 A ME P16716A ME 02508 B ME02508 B ME 02508B
- Authority
- ME
- Montenegro
- Prior art keywords
- trihydroxybenzyl
- hydrazide
- acceptable salts
- well
- physiologically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 2
- 239000003814 drug Substances 0.000 title claims 2
- 150000003943 catecholamines Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 5
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 4
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 4
- 239000002532 enzyme inhibitor Substances 0.000 claims 4
- WTDRDQBEARUVNC-QMUVANLASA-N (2s)-2-amino-2,3-dideuterio-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@]([2H])(N)C([2H])C1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-QMUVANLASA-N 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims 2
- BUZLUQORXILCMY-LBPRGKRZSA-N (2s)-2-amino-3-(4-hydroxyphenyl)-n'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide Chemical compound C([C@H](N)C(=O)NNCC=1C(=C(O)C(O)=CC=1)O)C1=CC=C(O)C=C1 BUZLUQORXILCMY-LBPRGKRZSA-N 0.000 claims 2
- BNQDCRGUHNALGH-LURJTMIESA-N (2s)-2-amino-3-hydroxy-n'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide Chemical compound OC[C@H](N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-LURJTMIESA-N 0.000 claims 2
- VEWUMDXDCNJDHA-UHFFFAOYSA-N 2-amino-n'-[(2,3,4-trihydroxyphenyl)methyl]acetohydrazide Chemical compound NCC(=O)NNCC1=CC=C(O)C(O)=C1O VEWUMDXDCNJDHA-UHFFFAOYSA-N 0.000 claims 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 2
- 229960000911 benserazide Drugs 0.000 claims 2
- 229960004596 cabergoline Drugs 0.000 claims 2
- XMRLUNALKLDUPT-UHFFFAOYSA-L calcium;5-butylpyridine-2-carboxylate Chemical compound [Ca+2].CCCCC1=CC=C(C([O-])=O)N=C1.CCCCC1=CC=C(C([O-])=O)N=C1 XMRLUNALKLDUPT-UHFFFAOYSA-L 0.000 claims 2
- VIKKBVWEWMBLAT-UHFFFAOYSA-N calcium;pentyl pyridine-2-carboxylate Chemical compound [Ca].CCCCCOC(=O)C1=CC=CC=N1 VIKKBVWEWMBLAT-UHFFFAOYSA-N 0.000 claims 2
- 229960004205 carbidopa Drugs 0.000 claims 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 2
- 229960003337 entacapone Drugs 0.000 claims 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims 2
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims 2
- 229960004644 moclobemide Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 2
- 229960003946 selegiline Drugs 0.000 claims 2
- 229960003741 tranylcypromine Drugs 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 208000005903 Manganese Poisoning Diseases 0.000 claims 1
- 206010027439 Metal poisoning Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010060860 Neurological symptom Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102100024819 Prolactin Human genes 0.000 claims 1
- 108010057464 Prolactin Proteins 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 102100038803 Somatotropin Human genes 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000017363 positive regulation of growth Effects 0.000 claims 1
- 229940097325 prolactin Drugs 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (5)
1. L-2-amino-2,3-dideutero-3-(3,4-dihidroksifenil) propionska kiselina i stereoizomeri, enantiomeri ili dijastereomeri u optički čistom obliku, kao i fiziološki prihvatljive soli od toga naznačeni time što su za korišćenje kao medikament.
2. L-2-amino-2,3-dideutero-3-(3,4-dihidroksifenil) propionska kiselina i stereoizomeri, enantiomeri ili dijastereomeri u optički čistom obliku, kao i fiziološki prihvatljive soli od toga naznačeni time što su za korišćenje u lečenju Parkinsonove bolesti, sindroma nemirne noge, distonije, za inhibiciju sekrecije prolaktina, za stimulisanje otpuštanja hormona rasta, za lečenje neuroloških simptoma hroničnih otrovanja manganom, amiotrofične lateralne skleroze i multiple sistemske atrofije.
3. Jedinjenje nazanačeno time što je za korišćenje prema patentnom zahtevu 2, u kombinaciji sa inhibitorom enzima ili nekoliko inhibitora enzima, odabranim iz grupe koja se sastoji od D,L-serin 2-(2,3,4-trihidroksibenzil) hidrazida (benserazid), (-)-L-α-hidrazino-3,4 dihidroksi-α-metilhidrocinaminske kiseline (karbidopa), L-serin 2-(2,3,4-trihidroksibenzil) hidrazida, glicin 2-(2,3,4-trihidroksibenzil) hidrazida i L-tirozin 2-(2,3,4-trihidroksibenzil) hidrazida, entakapona, kabergolina, selegilina, moklobemida, tranilcipromina, kalcijum 5-butil pikolinata i kalcijum 5-pentil pikolinata, kao i fiziološki prihvatljivih soli od toga.
4. Farmaceutska kompozicija, naznačena time što obuhvata L-2-amino-2,3-dideutero-3-(3,4-dihidroksifenil) propionsku kiselinu i stereoizomere, enantiomere ili dijastereomere u optički čistom obliku, kao i fiziološki prihvatljive soli od toga, pored farmaceutski prihvatljivih adjuvansa i aditiva.
5. Farmaceutska kompozicija prema patentnom zahtevu 4, naznačena time što obuhvata nadalje inhibitor enzima ili nekoliko inhibitora enzima, odabrane iz grupe koja se sastoji od D,L-serin 2-(2,3,4-trihidroksibenzil) hidrazida (benserazid), (-)-L-α-hidrazino-3,4 dihidroksi-α-metilhidrocinaminske kiseline (karbidopa), L-serin 2-(2,3,4-trihidroksibenzil) hidrazida, glicin 2-(2,3,4-trihidroksibenzil) hidrazida i L-tirozin 2-(2,3,4-trihidroksibenzil) hidrazida, entakapona, kabergolina, selegilina, moklobemida, tranilcipromina, kalcijum 5-butil pikolinata i kalcijum 5-pentil pikolinata, kao i fiziološki prihvatljivih soli od toga.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006008316 | 2006-02-17 | ||
| PCT/EP2007/001555 WO2007093450A2 (en) | 2006-02-17 | 2007-02-16 | Deuterated catecholamine derivatives and medicaments comprising said compounds |
| EP07703542.6A EP1991522B1 (en) | 2006-02-17 | 2007-02-16 | Deuterated catecholamine derivatives and medicaments comprising said compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02508B true ME02508B (me) | 2017-06-20 |
Family
ID=38236462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-167A ME02508B (me) | 2006-02-17 | 2007-02-16 | Deuterisani derivati kateholamina i medikamenti koji obuhvataju pomenuta jedinjenja |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8247603B2 (me) |
| EP (2) | EP3101001B1 (me) |
| JP (1) | JP5248331B2 (me) |
| KR (1) | KR101411422B1 (me) |
| CN (1) | CN101384545B (me) |
| AU (1) | AU2007214622B2 (me) |
| BR (1) | BRPI0708071A8 (me) |
| CA (1) | CA2642593C (me) |
| CY (1) | CY1117995T1 (me) |
| DK (1) | DK1991522T3 (me) |
| EA (1) | EA017983B1 (me) |
| ES (1) | ES2587368T3 (me) |
| HR (1) | HRP20161039T1 (me) |
| HU (1) | HUE028777T2 (me) |
| IL (1) | IL193102A (me) |
| LT (1) | LT1991522T (me) |
| ME (1) | ME02508B (me) |
| PL (1) | PL1991522T3 (me) |
| PT (1) | PT1991522T (me) |
| RS (1) | RS55142B1 (me) |
| SI (1) | SI1991522T1 (me) |
| UA (1) | UA97795C2 (me) |
| WO (1) | WO2007093450A2 (me) |
| ZA (1) | ZA200806568B (me) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| MX2010013393A (es) | 2008-06-06 | 2011-06-21 | Pharma Two B Ltd | Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson. |
| WO2010009243A1 (en) | 2008-07-15 | 2010-01-21 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
| MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2883641C (en) | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9763904B2 (en) | 2013-02-05 | 2017-09-19 | Teva Pharmaceuticals International Gmbh | Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds |
| JP6704252B2 (ja) * | 2013-02-05 | 2020-06-03 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬 |
| WO2014174425A2 (en) * | 2013-04-24 | 2014-10-30 | Mahesh Kandula | Compositions and methods for the treatment of orthostasis and neurological diseases |
| EP3611159B1 (en) * | 2013-07-08 | 2023-01-25 | Auspex Pharmaceuticals, Inc. | Dihydroxyphenyl neurotransmitter compounds, compositions and methods |
| WO2015077520A1 (en) * | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Methods of treating abnormal muscular activity |
| CN105873589B (zh) | 2013-12-03 | 2019-11-01 | 奥斯拜客斯制药有限公司 | 制造苯并喹啉化合物的方法 |
| WO2015120110A2 (en) | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
| EP2918266A1 (en) | 2014-03-11 | 2015-09-16 | CDRD Berolina AB | Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease |
| GB201420341D0 (en) * | 2014-11-17 | 2014-12-31 | Evolution Valves Ltd | Valve arrangement |
| CN114767672A (zh) | 2015-03-06 | 2022-07-22 | 奥斯拜客斯制药有限公司 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 |
| CN106343013A (zh) * | 2015-07-19 | 2017-01-25 | 中国科学院上海有机化学研究所 | 一种粮食储存方法 |
| MX383906B (es) | 2015-10-09 | 2025-03-14 | Teva Pharmaceuticals Int Gmbh | Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson |
| CN105360267B (zh) * | 2015-10-09 | 2017-11-10 | 青岛振坤食品机械有限公司 | 一种全自动穿串机 |
| CN105862897B (zh) * | 2016-04-11 | 2018-01-16 | 江苏省华建建设股份有限公司 | 砂质泥岩地基浅基础原槽浇筑施工工法 |
| US20220047529A1 (en) | 2018-09-13 | 2022-02-17 | University Of Canberra | Methods of inhibition |
| SG11202105533YA (en) * | 2018-12-06 | 2021-06-29 | Senda Biosciences Inc | Decarboxylase inhibitors for treating parkinson's disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3699158A (en) | 1969-08-25 | 1972-10-17 | Merck & Co Inc | Selective deuteration of tyrosine, aspartic and glutamic acids |
| DE2049807A1 (en) | 1970-10-10 | 1972-04-13 | Hartmeyer H | Conversion of closed cell plastics foam to - open cell structure |
| DE2049115C3 (de) | 1970-10-06 | 1981-07-30 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Tokyo | Verwendung von Calcium-5-butylpicolinat und/oder Calcium-5-pentylpicolinat bei der Bekämpfung des Parkinsonismus mit 3-(3,4-Dihydroxyphenyl)-L-alanin (L-Dopa) |
| ES2042520T3 (es) * | 1986-06-10 | 1993-12-16 | Chiesi Farma Spa | Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo. |
| IT1226902B (it) | 1988-07-12 | 1991-02-21 | Mini Ricerca Scient Tecnolog | Processo per la sintesi del levodopa |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| DE10261808A1 (de) * | 2002-12-19 | 2004-07-08 | Turicum Drug Development Ag | Verwendung von L-DOPA, seiner Derivate und diese Verbindungen enthaltender Arzneimittel zur Prophylaxe psychotischer Erkrankungen |
| DE10261807A1 (de) * | 2002-12-19 | 2004-07-01 | Turicum Drug Development Ag | Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel |
-
2007
- 2007-02-16 BR BRPI0708071A patent/BRPI0708071A8/pt not_active Application Discontinuation
- 2007-02-16 LT LTEP07703542.6T patent/LT1991522T/lt unknown
- 2007-02-16 EP EP16170031.5A patent/EP3101001B1/en not_active Not-in-force
- 2007-02-16 DK DK07703542.6T patent/DK1991522T3/en active
- 2007-02-16 ES ES07703542.6T patent/ES2587368T3/es active Active
- 2007-02-16 PT PT77035426T patent/PT1991522T/pt unknown
- 2007-02-16 US US12/224,120 patent/US8247603B2/en not_active Ceased
- 2007-02-16 JP JP2008554702A patent/JP5248331B2/ja not_active Expired - Fee Related
- 2007-02-16 WO PCT/EP2007/001555 patent/WO2007093450A2/en not_active Ceased
- 2007-02-16 US US14/464,568 patent/USRE46555E1/en not_active Expired - Fee Related
- 2007-02-16 AU AU2007214622A patent/AU2007214622B2/en not_active Ceased
- 2007-02-16 HR HRP20161039TT patent/HRP20161039T1/hr unknown
- 2007-02-16 HU HUE07703542A patent/HUE028777T2/en unknown
- 2007-02-16 PL PL07703542T patent/PL1991522T3/pl unknown
- 2007-02-16 ME MEP-2016-167A patent/ME02508B/me unknown
- 2007-02-16 EA EA200801826A patent/EA017983B1/ru not_active IP Right Cessation
- 2007-02-16 SI SI200731819A patent/SI1991522T1/sl unknown
- 2007-02-16 KR KR1020087022011A patent/KR101411422B1/ko not_active Expired - Fee Related
- 2007-02-16 CA CA2642593A patent/CA2642593C/en active Active
- 2007-02-16 RS RS20160674A patent/RS55142B1/sr unknown
- 2007-02-16 EP EP07703542.6A patent/EP1991522B1/en active Active
- 2007-02-16 UA UAA200811184A patent/UA97795C2/uk unknown
- 2007-02-16 CN CN200780005912.6A patent/CN101384545B/zh not_active Expired - Fee Related
-
2008
- 2008-07-28 ZA ZA200806568A patent/ZA200806568B/xx unknown
- 2008-07-29 IL IL193102A patent/IL193102A/en active IP Right Grant
-
2016
- 2016-08-17 CY CY20161100808T patent/CY1117995T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161039T1 (hr) | Deuterirani derivati kateholamina i lijekovi koji sadrže navedene spojeve | |
| MX360289B (es) | Composiciones de tapentadol. | |
| MX2025001995A (es) | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo | |
| TW200505423A (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
| Bond et al. | LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia | |
| NZ597260A (en) | Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone | |
| WO2013003629A3 (en) | Methods and compositions for inhibition of bone resorption | |
| EA201100313A1 (ru) | Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом | |
| PT1326613E (pt) | Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos | |
| NZ610911A (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same | |
| EP3192506A3 (en) | Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative or 5-aminolevulinic acid as active ingredient | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| RU2012142811A (ru) | Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения | |
| RU2012125827A (ru) | Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| BR0311558A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica | |
| BRPI1008727B8 (pt) | derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson | |
| WO2008109991A8 (en) | Inhibitors of carnitine palmitoyltransferase and treating cancer | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| MX2009010450A (es) | El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento. | |
| WO2008030830A3 (en) | Sustained-release composition and method of use thereof | |
| TW200745097A (en) | 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | |
| WO2009015485A8 (en) | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer | |
| IL181155A0 (en) | 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase i?á | |
| WO2005042101A8 (en) | Composition and dosage form for sustained effect of levodopa | |
| EA200800783A1 (ru) | Композиция тразодона для введения один раз в день |